Enzo Biochem, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 20   

Articles published

ENZ 5.14 +0.03 (0.59%)
price chart
What Falling Estimates & Price Mean for Enzo Biochem (ENZ) - Tale of the Tape
One such stock that you may want to consider dropping is Enzo Biochem Inc. ( ENZ ), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
Related articles »  
Enzo Biochem Awarded Patent for Novel Vectors Involving Gene Therapy ...
NEW YORK, Oct 07, 2014 (BUSINESS WIRE) -- Enzo Biochem, Inc. ENZ, -0.39% today announced that the U.S. Patent and Trademark Office has awarded the Company Patent No.
Enzo Biochem Granted Patent For Novel Vectors - Quick Facts  RTT News
Related articles »  
Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter Results ...
NEW YORK, Oct 06, 2014 (BUSINESS WIRE) -- Enzo Biochem, Inc. ENZ, -1.95% will hold a conference call to discuss fiscal 2014 fourth quarter results, Friday, October 10, 2014, at 8:30 AM E.T.. To listen to the conference call dial 1-888-459-5609.
Related articles »  
Enzo Biochem Reports Strong Fiscal Fourth Quarter Results
NEW YORK, Oct 09, 2014 (BUSINESS WIRE) -- Enzo Biochem Inc. ENZ, -0.39% today reported results for the fourth quarter and fiscal year ended July 31, 2014, with continued solid year-end gains posted by both Life Sciences and Clinical Labs.
Related articles »  
Watch List: SandRidge Energy (NYSE:SD), Intel Corporation (NASDAQ:INTC ...
On 7 October Enzo Biochem Inc. (NYSE:ENZ) announced that the U.S. Patent and Trademark Office has awarded the Company Patent for novel vectors for gene therapy treatments for cancers, virus infections and genetic diseases.
Shining on Major News : Freeport-McMoRan Inc. (NYSE:FCX), Xerox ...
Enzo Biochem Inc. (NYSE:ENZ) on 07 October 2014 announced that the U.S. Patent and Trademark Office has awarded the Company Patent No.
Stockwatch: Globalstar, Inc. (NYSEMKT:GSAT), KCAP Financial Inc (NASDAQ ...
Enzo Biochem, Inc. (NYSE:ENZ) said Tuesday it was awarded a patent by the USPTO, which covers novel vectors for gene therapy treatments for cancers, virus infections and genetic diseases.
Related articles »  
Hot Watch List : Groupon, Inc. (NASDAQ:GRPN), Regions Financial Corporation ...
On Oct 09, , Enzo Biochem Inc. (NYSE:ENZ) reported results for the fourth quarter and fiscal year ended July 31, 2014, with continued solid year-end gains posted by both Life Sciences and Clinical Labs.
ContraFect Corporation Expands Senior Management Team
Prior to MSKCC, she was General Counsel at Enzo Biochem, Inc. (Enzo), a publicly-traded biotechnology company, from 2003 to 2012.
Related articles »  
After-Hours Earnings Report for October 9, 2014 : FDO, INFY, HELE, CMTL ...
Enzo Biochem, Inc. ( ENZ ) is reporting for the quarter ending July 31, 2014. The biomedical (gene) company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.07.
Related articles »